Transcription of JROSG10-2
{{id}} {{{paragraph}}}
Example: marketing
JROSG10-2
Japanese Radiation Oncology Study Group ( ) (A) JROSG10-2 5FU+MMC II A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal 113-8677 3-18-22 Tel: 03-3823-2101 (65021) Fax: 03-4463-7543 E-mail: 113-8677 3-18-22 Tel: 03-3823-2101 (65021) Fax: 03-4463-7543 E-mail: 2010 7 24 2013 7 27 2016 2 6 2018 1 23 1 0. I-III 5-FU Mitomycin C(MMC) 1) primary endpoint 2 2) secondary endpoint 1) 2) TNM (UICC 7 2009 ) T1-4N0-3M0 3) ECOG PS0-1 T1-4 N0-3 M0 20 80 PS 0-1 5FU+MMC 2 4) 20 75 76 80 5) 6) 7) 8) 9) 6MV X 1 1 5 IMRT SIB
2 4) 20歳以上75歳以下または76歳以上80歳以下で担当医師がプロトコル治療が可能と判 断する場合 5) 化学療法に耐えうる臓器及び骨髄機能を有する
Loading..
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: